Building computational solutions for powerful, accessible diagnostics.
Capture Tumor Biology
Multiplex IF Multiplex immunofluorescence captures 20–50 protein markers in a single tissue scan, preserving spatial context across the entire tumor microenvironment.
Multiplex immunofluorescence captures 20–50 protein markers in a single tissue scan, preserving spatial context across the entire tumor microenvironment.
AI-Based Discovery Platform
Cell phenotyping - classifying cells by protein expression
Spatial network - mapping cell-to-cell interactions
Biomarker scoring - quantifying expression patterns
Cell phenotyping - classifying cells by protein expression
Spatial network - mapping cell-to-cell interactions
Biomarker scoring - quantifying expression patterns
Clinical Test Optimization
Drag to compare: IHC staining vs. AI-computed spatial analysis
Drag to compare: IHC staining vs. AI-computed spatial analysis
Predict
Clinical Outcome
Outcome risk score
Predict therapeutic benefit
Outcome risk score
Predict therapeutic benefit
The MultivisionDx biomarker discovery platform is a patent-pending computer vision workflow that reveals patterns within complex biological images at high throughput. Developed for multiplex-stained tumor microarrays containing samples from hundreds of patients, the technology extracts and integrates information across spatial scales, linking subcellular protein expression, cellular interactions, and tissue architecture to capture the full complexity of tumor biology and the tissue microenvironment.
Published in Cell and recognized as the top biomedical study in Finland, the method identifies clinically significant tumor signatures and can scale to any solid tumor or tissue type.
The platform was built to overcome the most critical image-analysis bottlenecks in spatial biology data and to unlock the full potential of large multiplex datasets for biomedical and translational research.
First-in-class compound biomarkers for improved therapy decisionsBuilding on published research and validation in thousands of patient samples, MultivisionDx diagnostic tools translate biological discoveries into next-generation clinical tools that guide therapy decisions.
The MultivisionDx compound biomarker identifies patients at high risk of treatment failure in standard-of-care therapies, enabling them to be fast-tracked to more effective alternatives while avoiding unnecessary side effects. Our lead indication is head-and-neck squamous cell carcinoma, where few molecular diagnostics currently exist to guide treatment stratification. Additional indications are in development.